RSV Maternal Vaccine Cuts Baby ICU Admissions and Hospitalizations by Half

A maternal respiratory syncytial virus (RSV) vaccination program introduced in England has successfully cut intensive care admissions for newborn babies by half during its first full year, according to data released by the UK Health Security Agency (UKHSA) and reported across multiple medical outlets in April 2026.

The immunization initiative, launched in 2024, offers the vaccine to women starting at 28 weeks of pregnancy. By boosting the mother’s immune system, antibodies are passed through the placenta to provide immediate protection to newborns from the day they are born against severe chest infections caused by the virus.

Study Findings and Hospitalization Rates

According to a UKHSA study following nearly 300,000 babies born between September 2024 and March 2025 across England—representing roughly 90% of all births during that window—over 4,500 infants required hospital treatment for the virus. The vast majority of those severe cases occurred in infants whose mothers had not received the vaccine.

While Medscape and other medical publications reported a 50% drop in newborn intensive care admissions, BBC News coverage noted that the overall pregnancy vaccine program reduces baby hospital admissions for RSV by more than 80%. Additional analysis from the UKHSA showed that protection climbs to nearly 85% when the jab is administered at least four weeks before birth, though shorter intervals still offer meaningful defense for infants born early.

Public Health Context and Uptake

RSV is a leading cause of infant hospitalization before the age of one, frequently causing lung inflammation that leaves babies struggling to breathe and feed. Dr Conall Watson, national programme lead for RSV at the UK Health Security Agency, described the severe manifestation of the virus as deeply frightening for parents watching their infants strain for oxygen.

Despite the demonstrated efficacy of the rollout, uptake varies geographically. Recent figures cited by health officials indicate that approximately 64% of pregnant women in England receive the RSV vaccine, but coverage drops to 53% in London. Health authorities continue to encourage expectant mothers to discuss the immunization with midwives during routine 28-week appointments.